Volatility Spikes As Rates Drop… And China’s Growing Chip Demand 10/16/25

16 Oct 2025 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Summary of CNBC's "Fast Money" Episode: Volatility Spikes As Rates Drop… And China’s Growing Chip Demand (10/16/25)

Episode Overview In this episode, the hosts discuss significant market movements, including volatility spikes, a drop in Treasury yields, and the implications for various sectors, particularly in light of rising chip demand from China.

Key Topics Covered

  • Market Reactions:
  • The S&P 500 experienced significant volatility, with swings nearly 2% from high to low.
  • The VIX, which measures market volatility, surged above 25, indicating heightened investor concern.
  • Treasury yields fell, with the 10-year yield dropping below 4%, signaling a potential flight to quality among investors.
  • Regional Banking Concerns:
  • The episode highlights issues with regional banks such as Western Alliance and Zions Bancorp, which faced scrutiny over problematic loans, raising credit quality concerns and impacting their stock prices.
  • The hosts debate whether these banking issues indicate systemic risks or are isolated incidents.
  • Artificial Intelligence (AI) Market Upside:
  • Dan Ives of Wedbush provided insights into the booming AI market, driven by high demand for NVIDIA chips in Asia.
  • The episode emphasized the impact of AI on various tech stocks and the broader market.
  • Lululemon's Performance:
  • Analysts downgraded Lululemon due to worsening traffic trends and competitive pressures in the athleisure market.
  • The stock has seen a significant decline, raising questions about its future potential.
  • Biotech Developments:
  • The episode features a discussion with the CEO of Madrigal Pharmaceuticals on their liver disease drug's market potential and competition in the biopharma sector.

Key Insights Market Dynamics

  • Volatility Indicators:
  • The elevated VIX suggests that investors are wary of underlying market conditions, even as broad indices remain stable.
  • Falling yields may reflect investors seeking safer assets amid uncertainties.
  • Regional Banks Under Pressure:
  • Concerns over credit quality and loan performance in regional banks could signify deeper issues, although some participants argue that these may not be systemic.

AI Sector Growth

  • Chip Demand:
  • AI is driving unprecedented demand for semiconductor chips, particularly from NVIDIA, suggesting a strong growth trajectory for tech companies involved in AI solutions.

Biotech Landscape

  • Market Opportunity:
  • The CEO of Madrigal Pharmaceuticals highlighted the expanding market for liver disease treatments, indicating a robust competitive environment that could support multiple successful entrants.

Conclusion The episode captures a moment of significant market fluctuation influenced by macroeconomic factors, sector-specific developments, and evolving investor sentiments towards technology and biotech industries. The discussions reflect a blend of caution and optimism as traders navigate a complex market environment.

Key Takeaways

  • Investor Sentiment:
  • A cautious outlook prevails among traders, influenced by regional banking issues and broader economic concerns.
  • Sector Focus:
  • The AI and biotech sectors are viewed as potential areas of growth, with significant investment moving towards companies positioned to capitalize on rising demand.
  • Lululemon's Challenges:
  • Increasing competition and a shift in consumer behavior pose challenges for Lululemon, necessitating a reevaluation of its market strategy.
  • Ongoing Market Monitoring:
  • Participants emphasize the importance of staying alert to macroeconomic indicators and sector-specific developments that could influence future trading strategies.

This episode of "Fast Money" provides valuable insights into current market trends, the implications of fluctuating yields, and the evolving landscape of key sectors impacting the economy.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:02Live in the Nasdaq market site in the heart of New York City's Times Square this is fast money Here's what's on tap tonight. Major moves under the surface. While broad market indices held steady today, big moves in the VIX and Treasury yields caught our eye. What the action says about the strength of the rally and a regional route due to the drops in lenders like Western Alliance and Lions Banks suggest bigger credit concerns amongst the regionals. We'll debate that. Plus, more AI upside. Dan Ives of Wedbush lays out the case from his channel checks in Asia. Lululemon lagging after Wall Street downgrade.

0:33And Biotech's boom. We'll talk to the CEO of Magical Pharma about the sector's run and how he is dealing with growing competition. I'm Melissa Lee, coming to you live from Studio B at the NASDAQ. On the desk tonight, Steve Grasso, Courtney Garcia, Dan Nathan, and Guy Adami. We start off with a major market reversal for the second straight day. Stocks giving up early gains yet again as trade fears and a continued government shutdown weigh on investors. The S &P is swinging nearly 2 % from high to low and closing the day down more than half a percent. The action launching the VIX above the 25 handle, its highest level since May, though so far from the Liberation Day highs.

1:07It's a pronounced move in an otherwise tepid market. And yields are getting yanked lower the 10-year squarely, below 4%, and the two-year yield hitting its lowest level in more than three years. So do these moves in volatility and rates signal deeper concerns lurking beneath the surface? Guy, what do you think? I think they should. I mean, yields are going lower because it's a perceived flight to quality. We can probably all agree or disagree on that, but I think that's what's happening. But on a 40-point handle day, lower in the VIX, excuse me, on the S &P, understanding that from high to low, it probably reversed about 100 handles.

1:41There's no way the VIX should be at 25, in my opinion. So it is clearly trying to tell the market something. And this comes in the wake of last week's reversals that we talked about, some of the fundamental and technical damage it's done. And the fact that gold had the move that it had on a risk off day is absolutely concerning. So, yes, I'll think this will be a day or a week or so that we'll come back to in the months to come and say the market was trying to tell us all something. Yeah, and I don't think it's about shutdown or tariff fears. I think the market has been pretty comfortable with that, right?

2:13So we had all that going on and we had a VIX grind down to like the mid-teens or something prior to the tape bomb that we had on Friday. Obviously, we're going to talk about this regional banking thing. And, you know, for to be hyperbolic about this and what's going on, you know, this is probably a bit too early. If we take a page out of the playbook from March of 2023, we kind of know there's going to be support for this thing. Right. They're going to kind of figure this out. Some of the numbers that we're hearing about for these smaller banks don't seem to be particularly large. They don't seem like there's going to be systemic sort of risk.

2:44And I think maybe it's too early to say that. I'm not a bank analyst or, you know, look at these things pretty closely. But the only thing I'll say is that if we're about to lose a couple of these banks and then it looks like further than, you know, May or March of 2023, I think we lost a bank in May of 23 after a few. Then you have to say to yourself, what saved us back then? Yeah, there was a little bit of QT, but it was really the interest in this AI trade. And at this point, I don't think AI can save this sort of situation. And I don't mean to sound so dire, but look at the way these stocks traded.

3:15Look at the way it took down some of these large money center banks, especially after what we heard from them earlier in the week. So it just feels like investors are looking for reasons to kind of sell right here. But when you see the sort of pain that we saw on Friday and then here in other sectors, that should get your antennas up a little bit. Yeah, I think you're right. People are looking for a reason to sell. I mean, the markets have done so well this year. At some point, you're going to see some profit taking. But I also think on the flip side, you are seeing these large amounts of cash that are sitting on the sidelines.

3:41And a lot of that is from institutional investors, just still left over from Q1 and Q2. They're hoping for some sort of 10 % correction that they can buy on because they don't want to be sitting on this cash if markets keep going straight up. I think that's why you're seeing these up and down moves, because you're going to continue to see these dips bought. So I actually am not overly concerned about this. I do think you're going to see some profit taking here, but I don't think this is going to be longer lasting. So I'll go back to yields. I think it is safe haven. I think it's about China. Maybe a little bit about government shutdown, not much.

4:11Also, the Fed's going to be lowering rates. I think yields are probably getting ahead of that. And what else are they going to be doing? Ending QT. So I think the market's getting ahead of that as well. Do you know it's rarely that you see the 10-year below the Fed funds rate? And we see the two-year really goes in lockstep, but it's rare that you see the 10-year below it. So that dropped as soon as they started to lower rates. We went from four and a quarter percent in the Fed funds rate and you saw the 10 year drop and now it's below four or around four. But the Fed funds rate is around four to point one.

4:48So I think this is all normal. It's all normal. No biggie, huh, Guy? No biggie. I mean, it's a bond market. Maybe it's normal. You know, again, Fed can do what they want. I think rates are going lower because people are scared of something. And I think that's what the gold market's been saying for a while. I think it's this flight to perceived quality, which may or may not be the right thing to do. That time will tell with that one. I'll say this to Dan's point about the banks. If things were as robust as the market until today suggests, KRE should not be at levels we last saw in August. The all-time high being made three years or so ago.

5:21Think about that for a second. So if you have all this M &A activity, if the bank, if the environment is – Things are so great for the large money centers. They should be better for the smaller banks, and they're not. So why? Maybe it's the yield curve a little bit, right? So to your point about yields getting broke that double bottom. And, you know, but we would have seen more caution, I think, at the end of the day. The one thing I'll just say, if you kind of just connect some of the dots. All right. So you have this regional thing. You've already had these private equity names, these private lending sort of names acting very, very poorly.

5:51And the way the money centers gave up some of those gains, I think at some point you have to start asking the question, like, how much leverage is in the system? And, you know, we had Thomas Shodan last night from KBW, and we asked him a bunch of questions about deregulation and what's going on here. And, you know, my view is that you give these banks enough rope, they're going to hang themselves. Like, this has been the story of the last 20 years. And so when I think about what's going on here, listen, again, I don't know if there's anything brewing under the hood. But if you have business loans that are weak and they're starting to fail, we have a labor market that's already somewhat of a concern.

6:26and you start to see this lower end consumer having a difficult time, delinquencies ticking up, that sort of thing. It doesn't make for a great backdrop investing in equities right here. And we're only 2 percent off the all time highs. All right. For more on the moving rates that we saw today, let's bring in CNBC's Rick Santelli. He joins us today from the CME. Rick, it's always great to see you. You've always made that, you know, the metaphor of the balloon. You push it down underwater, pops back up. But here we are. We close below four. Yeah. No, we have. And let's go through it, shall we? Real quickly, I want to go through the charts.

6:58September 1st with regard to two-year notes of 22. So fresh three-year lows. We'll stay at three-year lows if we see yields at these levels because September of 2022 and the previous months, we were much lower. October 1st of 24 for a 10-year. But the most important chart of the day is an X1. Year-to-date SOFR. Secured overnight funding rate. Now, let's go through everything. Guy talked about all the issues of banks and whatnot, and I agree with that. We had two regional banks today. Think about loans. What prices loans? Dan talked about that. Many of these loans are priced off SOFR. And Steve talked about the spreads between the effective overnight funds rate and what's going on in 10s.

7:44Well, think about it. With the Fed overnight fund rate, now we're at widening spread with SOFR, which is above it. All these things come at a time where we had historically tight credit spreads. Fed's now talking about no more runoff on the balance sheet. I wonder why. And Fed lowering rates and trying to ease credit. And what's the market doing? Right as they do that, it's tightening credit. Now, I think Courtney's right also. I think the economy's going to have great fundamentals in a couple of months when the big, beautiful bill starts to pay us some dividends. But I think it could be a little dicey in between then and now.

8:21The Czech oil light, Czech engine light is on on the U.S. economy. But I don't think it's that, you know, the engine's going to break down. We need a little more oil in the crane case because SOFR is basically the oil in the gears of the funding market. And I think that's really what's going on today. So if you ask me how long rates are going to stay under 4 % or how long the two years is going to continue to make strides against three-year historic lows, I think as long as some of these funding issues remain. But I do think that stubborn long rates is here to stay once we get past this chapter.

9:01So this chapter, Rick, will then yield rates that are, what, back in the range of 405 to 420 or so? I mean, I'm just trying to figure out, like, how long is this chapter? Because it seemed like everybody wanted to sort of write off tricolor and first brands and not really think about the impact. And then we saw J.P. Morgan talk about it. We saw all the big banks talk about it. We see Western Alliance and Zions. Maybe it's a little idiosyncratic in terms of their exposures, but they're talking about credit quality in a way that investors care. And we see it result in tighter credit. Yeah, you know what?

9:38It's a big grab for good quality collateral. And you know whether it was gold moving up or the fact that silver was trading$128 when the futures markets were trading significantly less. The whole thing with dollars being in demand but yet the dollar index going down. I think all these things are odd things. But I think in the end what we need to concentrate on the most is that everybody rejoiced when we had what? Close to a$200 billion monthly surplus. But what we're not talking about is when this fiscal year ends, we're going to be spending$1.22 trillion on servicing the debt. Those are the dynamics that we ultimately are going to continue to price the long rates on.

10:22Rick, always great to speak with you. Thank you. Thank you. Rick Santelli. Regional banks, as we mentioned, the biggest losers in today's action. Zion Bancorp, Western Alliance getting crushed after both banks disclosed problematic loans in their portfolios, raising concerns over credit quality and potential charge-offs. Those stocks sending the regional bank ETF KRE sliding nearly 7 percent, its worst day since April. For more on the troubles facing the group, we're joined by Chris Maranak of Jannie Montgomery Scott. He is the firm's director of research. Chris, great to have you with us. You heard Rick and you heard him talk about SOFR.

10:54How does this connect? When you take a look at that graph and you take a look at the action in regional banks, it doesn't paint a pretty picture. What's your take? Well, today it's a negative picture because of the explosion of SOFR and these concerns. I think that we've seen SOFR go back and forth many times, including back in April. If you go back to 2023, we had a lot of chaos for a few months, March, April, and May. And then we gave all that negativity back and we rallied from that. Because the fundamentals of the banks are they have a lot of capital and a lot of reserves and a lot of earnings to sort of handle this noise.

11:29I agree. I don't think that it's idiosyncratic or one-off. These things are going to happen. Credit is not pristine, nor should it be. The banks are levered 9, 10 to 1. They're going to have errors, and they're going to recognize them. I think a lot of the negativity for banks tends to be unfounded because it's a very short cycle of recognizing the issues and then moving on to the next task. And I think the task for most banks is to continue to make money, buy back stock. And I think the tightening of credit is going to be temporary. I think that, as Rick mentioned, collateral builds character, and that's always been true in banking.

12:05So I think we're going to see that the better borrowers can get access to capital, and those who are going to struggle are already struggling. And I think that many of the banks have less leverage heading into this cycle, so I just don't think it's going to be as ugly. But days like today will happen. It's just part of the game for banks. Yeah, Chris, I hear what you're saying, and I would agree wholeheartedly if the KRE was coming off from an all-time high. but it's not. This is an ETF that made an all-time high in February of 2022. Obviously, the S &P is significantly higher than that. The larger banks are much higher than that.

12:37They've underperformed. And oh, by the way, these are banks that should be theoretically doing well if there's going to be all this M &A activity that everybody is hoping for. So why the continued underperformance, forgetting about just the last week? Well, for one thing, Guy, I don't think that the whole sector has reported enough earnings for people to see where the whole capital stack is. I also think to some extent we've seen companies like Fifth Third a month ago recognize that almost 100 % loss on Tricolor, raise their dividend two days later, and then buy Comerica a month later. So there are ways to self-heal the process.

13:12I think there still will be M &A, and I think there still will be progress in the banks. The stocks are off because everyone sort of crowds into the same trade temporarily, and it works. It worked beautifully today. So that's great. Tomorrow's another day. I think you'll see these stocks rally on the back of the fundamentals and a little cooling off of these concerns, because there isn't likely to be 20 problems that are like tricolor first brands and others that have popped up. There will be more. I'm not saying it's zero. I just don't think it's going to be a plethora, because we're at a different phase of the cycle where some problems emerge, but it's still going to be relatively limited.

13:48So even with the explosion of private credit, Chris? You don't think that the loans that have been extended and made are any worse in quality to companies that maybe you have a worse balance sheet? I mean, I'm just trying to figure out how you have such certainty that this problem is going to be less. I understand on the bank side of things, their balance sheets and their leverage, their balance sheets are much better. Their leverage is much lower than previous cycles. But at the same time, you have, on the other hand, an explosion in private credit where there's so much money flowing in and there's just a reach for deals and loans to be made?

14:20So I think at the end of the day, the credit answer is it goes back to frequency and severity. How many problems, that's your frequency, and then what's your severity of loss? When you have fraud like Tricolor, the severity is almost 100%. When you have other situations like commercial real estate, it's a lot lower. You know, things were not as ugly at New York Community Now Flagstar than people thought a year and a half ago. And I think that'll play out in some of these other concerns. On private capital, they are lending a higher leverage for a higher interest rate. The banks are sort of being blamed and labeled into that when the banks are really lending on lines of credit with a much better security position.

14:57I think a lot of companies are doing senior secure deals. And yes, they will be hit by fraud. Those fraud incidents will be painful, but they'll be few and far between. I think the structure of how private capital is tied into the banking industry is going to ultimately be better than folks understand. But it won't be perfect. it will have some issues and some bumps and bruises associated with play. You gave the example of Fifth Third is self-healing, Chris. And so I'm wondering if you go out on a limb and you say Western Alliance is a buy or Zions is a buy. Sure. I think both of those stocks can rally.

15:32I think you're going to see that they both build capital. Most of the midsize banks have built capital 100 to 120 basis points since Silicon Valley failed. And their shares have gone down in terms of both price. but also the share count has come down. Many banks are buying back stock hand over fist. And I think days like today actually encourage CFOs to buy back more stock, which I think will be another theme that comes out of this episode today. Chris, great to have you. Thank you. Thank you as well. Chris Marinak, Janie Montgomery. So where do we go on the cap scale? Do you go with the large money center banks or do you go with the regionals, which seemingly have more perceived problems, let's say.

16:12Yeah, well, since, you know, SVB, you really don't want to go with the regionals. And now this is another reason why you will stay away from the regionals. I wouldn't go with the regional, even though you're going to find probably some outsized performance buying them off the bottom when they're all hit with the same stroke. There's no reason to buy those. Stay with the money setter banks. They're the safest asset. They have the most capital. We've got some breaking news here we want to get to. President Trump making some comments on weight loss drug prices. Eamon Javers got all the details. Eamon.

16:40Melissa, some of the drug makers are moving on this news. A bit of an unusual moment just now in the Oval Office. The president was speaking at an unrelated event about IVF, and he was asked by a reporter about the prices for drugs related to weight loss. The president said that those prices are going to be coming down significantly and that he was working on a deal around that. Then Dr. Oz, who is now the administrator of the Centers for Medicare and Medicaid Services, stepped up, kind of interrupted and said, well, we don't have a deal just yet. It's sort of an unusual moment. Nonetheless, you can see there, shares are moving on this moment.

17:19So I want to play you that exchange. Here it is. They'll be much lower. They'll be much lower. We have not negotiated those yet. We're going to be rolling these out over time. the GOP category of drugs, which includes Ozemek, have not been negotiated yet. What's the timeline for that? It will. It'll come down, like everyone else. Okay. Any timeline on those negotiations? No, but I think those are going to come down pretty fast, and we do have, I guess, some alternative. The president will be happy with the result, and until he is, we're not going to close those negotiations. So the dynamic there, Melissa, pretty clear.

17:52Dr. Oz not wanting to say that a deal has been done, saying that the negotiations are still ongoing, And the president really wanting to assert that those drug prices are going to come down. That may be why you see what you're seeing on your screen right now. Eli Lilly down over 4.6 percent right now. And, you know, you see Novo also down 3.7 now. So clearly investors are looking at that exchange and saying, well, the president knows something about where this is going and we ought to pay attention to it. Eamon, thank you. Eamon Javers in Washington. You saw the swift drops in the stock prices directly in reaction to this news.

18:29You know, this is a sector, the pharmaceutical sector, where we thought everything was sort of in the clear. The base cloud has lifted. And here we are, the president, reminding investors that all he has to do is say, we demand lower prices and that's going to impact the results. We're going to hear from Eli Lilly at the end of the month. I mean, we've said for a long time that they're trading at two or three times turns more expensive than big cap pharma. and that, you know, something goes wrong on the GLP front, they're going to suck. Now, I didn't see this one coming, but you get headlines like this, you're going to see that type of reaction.

19:00So there's no catalyst into earnings. I'll say this, although all big cap pharma get lumped into a single ETF, which would get dragged down by the weighting of Eli Lilly, Merck's and Bristol's and Pfizer's actually should sort of win to this in the longer run. And I'd be curious to see what the negotiations actually come to. Like, are they going to get anything like expanded coverage for what they can actually sell these drugs for that they even if it's a lower price, will it help them or will offset some of that? So I think when you get some of these headlines, you get these knee jerk reactions.

19:28I don't think it's necessarily something to fear right away. But I think whether it's the pill versions of these these drugs or if they're getting under Medicaid coverage or just more symptoms that they can cover for, I think that's actually going to be a bigger thing for these stocks. This sounds a lot like democratic socialism. This is a debate that's going on, especially in this city. But I will tell you that I have to imagine that both sides, this is a very popular sort of thing. You know what I mean? It's like kind of keeping down the price of oil. But again, how is that your point? It's like when this administration comes to you, if you're a company, whether you're public or private, you can't say no to them.

20:04I mean, so you're in a position that's really difficult. And there might be some situations like this that are uneconomical for these companies. I don't want to say crazy, but what's so interesting is that Eli Lilly has already decided that it's going to invest a lot in new manufacturing facilities in the United States. And we thought that it would be in the clear because of that. And it's still in the crosshairs. It's like Dan said, it's a bipartisan issue. It's like oil. Everybody wants lower drug prices, whether you're on the right side of the aisle, the left side of the aisle. This is where it's going.

20:34Everyone agrees on this. There's very few things that are bipartisan. This is one of them. Coming up, another big day for Oracle. what analysts are hearing about the company's AI push and how that stock is responding. We've got the details next. Plus, demand hitting the mat, why Wall Street isn't holding its breath for a rebound in Lululemon and whether the stock will stay in downward dog. Don't go anywhere. Fast Money is back in two.

21:00Welcome back to Fast Money. Oracle shares up 3 % today after the company gave some updates on its AI business. At its analyst day, the company also confirmed a cloud deal with Meta shares, though, still up about 10 percent off, I should say, their post-earnings peak last month. Sima Modi is here with all the details. Sima. This was an important update, Melissa. Executives revealing gross margins for that important cloud infrastructure business will be in between 30 to 40 percent, while revenue in 2030 is expected to reach$166 billion. This same business, by the way, brought in just$10 billion last year.

21:32So the bottom line is that revenue is accelerating rapidly. gross margins are much better than feared, sort of throwing cold water on that report last week that suggested weaker margins due to the cost tied to buying hundreds of thousands of AI chips from NVIDIA and AMD. And just moments ago, founder and chairman Larry Ellison commenting on the fact that Oracle does it all from building data centers, training the AI models, empowering the database. He adds that, quote, none of the other three big cloud vendors do that. They are primarily tech platform. So throwing a bit of shade on his competition.

22:03Ellison, of course, referring to Amazon, Microsoft, and Google that had their competing cloud platforms. Now, with today's gains, the stock is now up over 80 % on the year, and the company's CFO previewing that Oracle could see even more larger scale opportunities signed over the next 12 months. So they're sort of leaving the door open to another update in terms of higher guidance. What was the tone amongst the analysts question, Seema, when it comes to having the money to pay for all of these things? Well, here's the thing. We were not expecting Oracle to detail margins for their Oracle cloud infrastructure business, because in the past, they haven't really disclosed that number.

Read the full transcript

22:40So the fact that they went for it and said, we expect a range of 30 to 40 percent, which is higher than what the information was reporting last week. It is higher than what Wall Street consensus is. That level of clarity provided some reassurance to investors who, of course, are having this discussion around the stock is up so much, they continue to increase CapEx because there is this need to continue to buy these high-performance GPUs to stay up with their competition. But the fact that they're showing that there are these long-term profitability targets they can potentially reach, that's been working for the stock.

23:10Seema, thank you. Seema Modi. Dan, I'm going to go to you on this. I feel like you've got some insights. So the information was reporting that 16 % or so. Yeah. And so 30 to 40 seems like a really tough road to hoe. And when you think about what they're suggesting is that they're this full stack, a lot of that stack is really low margin. Go and look what Supermicro is doing. Go look at what Dell is doing. Look at what Hewlett Packard, we saw that the other day, right? Listen, this is a lot of stuff on the come here. So I remain very skeptical. I don't know how you take a distant fifth cloud provider.

23:44You give them all these contracts. They have to spend tens of billions of dollars on gigawatts that they haven't done a whole heck of a lot. They got to secure the power, all this sort of stuff? So I'm sorry to interrupt. But they're saying 30 % to 40 % on cloud margin. But you're saying the rest of the stack has lower margins. Yeah, of course. And so the blended margins is lower. Yeah, I mean, like, listen, you know, this is like, this is the last one. I mean, like, so we had all the hyperscalers. We had Meta. They did the Neo clouds. Now they're getting to Oracle. And to me, this just seems like, I don't know, they're going to be the patsy on this whole thing.

24:14The market just needs to hear that they refute the margin topic. Once they do that, the stock ramps right back up. And that's what you're seeing right now. So I would probably, although I agree with Dan, you kind of have to hold your nose and just buy the stock because it's all about margins. If they can prove they have the margins they say they have, the stock goes higher. All right. There's a lot more fast money to come. Here's what's coming up next. Lulu losing balance. Why Wall Street isn't loving the stock's pose over the last year and why they're not holding their breath for a demand rebound.

24:46Plus, AI moves from the mainland, what a top tech analyst sees in China chip demand, and the semi-stocks poised to benefit. You're watching Fast Money, live from the NASDAQ market side in Times Square. We're back right after this.

25:18Welcome back to Fast Money. We've got a call of the day on Lululemon. Bernstein downgrading the athleisure brand to market performance, setting markdowns and worsening traffic trends. Analysts also pointing to uncertainty over a spring launch of a new product line from a, quote, unproven designer. Bernstein cut its price target on Lululemon to$190. Shares are down nearly 57 % this year. Courtney, is this a turnaround story? Do you see anything in it that can turn around? I mean, people are hoping it's a turnaround story, but the competition is just gearing up. I mean, you already have like Aloe and Viore, but now you even have Nike who's partnering with Skims, which is really trying to get into this business.

25:53I do think though, on the other hand, when you look at how much this is down, right? Because Lululemon's down like almost 60 % this year. It's now trading 13 tight in forward earnings, which is a lot lower than historical averages. I do think at some point you can probably look at this as like, is all of the bad news priced in? So I don't know what the upside's gonna be, but I do think the valuation might start to look attractive here. Yeah. The problem is that they promised newness to come and that newness is not going to come for like six months. So what do you do in between? Yeah, I think, you know, court nailed it.

26:23There's too many non-public companies that are competing with it. Right. She named them all. And then the bulls will look towards China. So China sales are growing. But China went from two percent of total sales back three years ago to 16 percent. Now, just not enough to move the needle. Too much competition. I don't know if the new unknown talent person is going to be able to move the needle, but I'd stay away from the stock. All right. Well, you know what? We're getting ready for a Fast Money Live Trading the Holidays event on December 11th and hot off the press. Guess what it is? So freaking hot.

26:56It's in my head. Look at this. Our 2026 Fast Money calendar. I don't know if they can Zoom. I mean, it cracks that. I just got. Look at this thing. It's unbelievable. Everybody's got their own month. Every date that we got fed meetings, we got like all the real stuff, the big sporting events, the real stuff like economic data. But the important stuff is like our birthdays. Our birthdays. For example, you could find out when Courtney's birthday is. Right. Or Steve's birthday. Dan Nathan actually has a birthday. Yes. As curmudgeonly as he is. Look, we're flipping through this thing now. He has a hatch date.

27:25By the way, I don't even know how many. I don't think there are a lot of seats left. But to the extent that they are. I thought we were sold out. You're going to get a calendar in addition to all the others. I'm telling you. I'm telling you. Yes. Everyone. It's crazy. if you call in in the next two minutes. And there are pictures of Melissa Lee that I've never seen before that I think you'll be interested in. Oh, my God. Just saying. Come on. It's a very deceptive tease. Creep. No, what? It's true. I have not seen those pictures. Anyway. People might be interested in them. You know, you can get one of these calendars at the event, and we can sign the month that we are featured in.

27:58So that is very exciting. So you can get your tickets now while they are still available. They're almost sold out. Go to cbcevents.com slash fast money or scan the QR code on your screen. Coming up, China's chip demand and the stocks that will benefit. Our next guest lays out who he sees gaining ground from the mainland. More Fast Money in two.

28:29Welcome back to Fast Money. Stocks are raising earlier gains and closing lower. The Dow falling more than 300 points. The S &P and Nasdaq both down about a half a percent. Bitcoin continuing to pull back, now trading around$108 ,000, down more than 10 percent over just the last two weeks. The rest of the crypto space lower as well. And shares of Salesforce jumping nearly 4 percent. The company upping its revenue forecast for the next few years, saying it now expects revenue of more than$60 billion in 2030. CRM stocks still down more than 25 percent this year. And some after hours action shares of CSX and interactive brokers on the move after tapping EPS and revenue estimates.

29:05Steve, I know you wanted to talk about the fall in crypto here. Yeah, you know, I think that, you know, guys had a good run with gold. And this has been a long time coming. And it's just just blowing the doors off of performance. That's trading like a safe haven asset. Crypto is trading like a risk asset. And we do need rates to start ticking lower to make crypto a little more valuable. But right now it's technical. It's fundamental if you can mention that, if you're talking about crypto in the same sentence. I think we will rally back, but it could take another couple of weeks to a month. I wanted to quickly touch on CRM, if we could, because giving a forecast for 2030 seems ambitious, Guy.

29:44I don't know what you're saying. Well, I mean, we just heard from Oracle. Apparently, they have clarity out to 2030. I'm hard-pressed to believe that anybody does, but Salesforce being one of them. I mean, a lot can change from now. Listen, a lot can change from now until the spring of next year in terms of just the employment picture and a lot of things. that would impact Salesforce. So the fact that they're that adventurous to go out that far is one thing. I'll say this, though, in terms of the stock. 235 has been a level a couple times we've held. Technically, I think it looks okay. Valuation is still a concern.

30:12The market has been telling you for like two years with Salesforce that they are one of the ones that's going to be disrupted. And that's, to me, like, I think that they probably give back a lot of these gains from today. What which is Dan Ives out with a new bullish note on the AI trade as he's been conducting his channel checks in Asia. He is the global head of technology research. He joins us from Hong Kong. Good morning to you, Dan. Great to be here. So what you found supports the bullish case for AI. Is that what you've been finding? Yeah, I'd say overall in the region, look, demand to supply for NVIDIA chips, it's about 10 to 1, potentially 12 to 1.

30:49Look, we do these trips three, four times a year. It's about what demand looks like in the region from production. what it's the use cases that are driving it, but it comes down to on the hardware side, right? And that's super bullish for Nvidia. I think Street's underestimating numbers by anywhere from 20 % to 30 % next 12 to 18 months. And most of what I think this also means is like on the hyperscalers, in terms of everything we've seen from Microsoft, from Google, from Amazon, obviously Oracle that you saw today, I mean, we're only in the second inning of this all playing out. And all of our checks are just giving us more and more bullishness that this is going to continue.

31:26I think streets underestimate it. So, Dan, can you elaborate on where you're doing these channel checks? Because if there are export controls, what chips are you talking about? Where are these channels that you're checking? Yeah. I mean, if you look, especially in Taiwan and what we're seeing from NVIDIA, I think it all comes down to what does demand supply look like? Now, obviously, you have the controls in terms of China, and that continues to be a question mark. But my view is that what does demand look like in the region? And I think what I compare it to even three months ago, it's probably up 20%.

32:05And I think what that shows that this demand that we're seeing across the region, especially from a production perspective, you can't argue with the demand. And the demand's being driven by the use cases. It's being driven by, obviously, big tech spending. But I think if there's a sort of a headline here, it's not slowing down. I think CapEx is going to be significantly underestimated now going into next year. And that's bullish for NVIDIA, bullish for AMD, bullish for TSMC, and, of course, on the hyperscaller side. And then you look at names like Palantir, Snowflake, Mongo, the consumption use case plays.

32:40That's why I think those continue to be just pounding the table as a broader group. Hey, Dan, I hope you're doing dim sum for breakfast because that's how— That is breakfast. I know, but I had to go to Hong Kong to learn that. So I hope you're enjoying breakfast. Question about Huawei. What are you hearing there? What are you hearing about the chips that they're, you know, basically creating to compete with NVIDIA and ultimately AMD? And, you know, we're in a situation where they basically have import controls right now. I'm just curious, like, what the vibe is out there. Yeah, it's a huge opportunity for Huawei, right?

33:14I mean, especially what's happened with big tech in China. And they're trying to narrow the gap. I think there's still, if you look where NVIDIA is globally, I think that continues to be the chip everyone wants. But look, it also speaks to like, you know, in our AI 30, we have Alibaba and Biden. Like, I think those are going to be two names from a China perspective, specifically Alibaba that is in a prime position for that to accelerate. But it just shows, look, this is an AI arms race playing out. And that's bullish from an investor perspective on both sides, whether it's China or U.S. All right, Dan, great to see you.

33:50Thank you. Great to see you. Safe travels. Dan Ives of Wedbush joining us from Hong Kong this evening. You just mentioned Snowflake on the call today, didn't you? Yeah, I mean, you're seeing companies across the board are just reiterating this demand that you're seeing for AI. And I think that story is continuing to play out. But I do think you want to be a little cautious as an investor with how much this is becoming, you know, associated with one another. So there's this circular financing, right, where these companies are lending to other companies who are going to be buying their products.

34:18So when these things are doing well, which they are right now, and that's where a lot of investors are taking that on the upside to the positive, but on the flip side, when these things go down, you can see these all go down in aggregate. So you're seeing this whether it's Snowflake, you're seeing this whether it's Oracle. I mean, things are really on the upside right now. But I do want to cautious investors. Many people just have so much more exposure than they realize to AI. So I'm not saying you don't want to have it. I'm just saying you don't want to be overexposed. Just make sure you know how much you own.

34:43You know, two or three years ago, we were talking about AI being pixie dust, right, in the market. And then it really gains some traction. The next thing for me is quantum. And I think that's where we see these stocks that are not mature yet, that are getting priced like startups, and people complain about overvaluation. This is the next AI trend. And this is going to be M &A amongst them by the AI companies. I like the quantum names. Coming up, how one company's liver disease drug is tightening the belt in the weight loss drug race and what the CEO sees in store for the biotech industry. He joins us next when Fast Money returns.

35:27Welcome back to Fast Money. Biopharma companies are betting big on drugs that treat MASH, a serious liver disease linked to obesity and metabolic issues. Several companies have snapped up experimental drugs this year, including Roche and Novo Nordisk, which each have agreed to acquire liver disease-focused companies and deals potentially worth several billion apiece. The moves follow a successful launch of Madrigal's drug, Resdivra, which was the first MASH drug cleared by the FDA back in March 2024. For more in the increasingly competitive space, Madrigal Pharmaceuticals CEO Bill Sibyl joins us here on set.

35:59Bill, it's great to see you again. Great to see you. Thanks for having me. So Wagovi was approved in August for the treatment of MASH. I'm wondering how things, if at all, have changed in terms of physicians' indications, in terms of their indications of interest in using ResDifera versus competitors? Yeah, well, look, having more entrants is really helpful. It drives awareness, treatment, and ultimately with the profile of product that we have with ResDifera, it helps us overall. So we've been talking about since launch steadily adding patients, and that's been the case since the launch of Wagovi as well.

36:31Okay, so there has been no change whatsoever. I mean, how do you regard the space in terms of having enough share for everybody involved? And at what point do you say they are competitors? Yeah, I mean, look, we have to think about what the market dynamics are. We talk about 315 ,000 diagnosed patients in the United States. In our last quarter call, we talked about having over 23 ,000 patients on drug. That's 7 % penetration into that marketplace. Now, the diagnosis rate, we estimate to be about 10%. So the number of prevalent patients out there that are waiting to be diagnosed is many times what we have already treated in the 23 ,000.

37:13So there's so much market development left that this can support multiple products entering it. And that will actually help drive diagnosis and treatment. So we're at the very beginning here. I mean, this is a market which is destined to be a big specialty market. If you think even of markets like rheumatoid arthritis, psoriasis, that are 25 years since the first launch, they have 15 products and they're over$20 billion in value. So look where we are now. In the last quarter, we said that we are on an$800 million run rate. This is really the beginning with 7 % penetration. So we need more companies to come in.

37:53We need more awareness. We need more innovation. And we're hoping to lead that. These companies that are entering the space or are trying to enter the space, they're large companies, very deep pockets and huge marketing budgets. And I'm wondering how you think about where you're positioned and how you're positioned. And, of course, the next logical question is, would you ever be one of these targets for a larger farmer company who's looking to expand their pipeline into a very hot area? So, look, in my career, I've competed against the biggest of big. That doesn't scare me at all. It doesn't scare us at all.

38:26So looking again at the fundamentals, we've got a great product profile, and we've hired a team that has scaled companies and products before. And that's really important. So we feel that we can compete. This is a specialty market. These 315 ,000 patients are being treated by specialists, hepatologists, gastroenterologists, some endocrinologists. And because of it being that targeted, we have the ability, a company our size, to very easily and adequately target them and be successful. And so far we have been. If you look at the metrics and we look objectively at the 10 best launches and specialty over the last 10 years, and we are tracking at or near the top of every metric.

39:09So this is objectively an outstanding launch. So we feel we can compete against anyone. And by the time the next competitor comes, we'll be that many more tens of thousands of patients into it. And this is hard work and you learn and iterate along the way. So we're going to be well, well, well ahead of anyone who comes in. We're happy to have them here and we wish them good luck. You opened eyes at that Morgan Stanley conference at the beginning of September. You said you had a half a billion dollars of financing, so you have some runway for sure. So things are good. What does Wall Street miss about your story?

39:40Like what are they not seeing? The stock is actually performing extraordinarily well, but what do you wish people saw and understood a little bit better? Well, I think it's they have to believe the market dynamics going back to that, which is this is a good size specialty population. As I said, 315 ,000, 10 % diagnosis rate. So it could be much larger. We have a product that is serving a very high unmet need. People are forgetting that MASH is the number one cause of liver transplants for women in the United States, number two for men. This is a serious disease. And we're focused on those patients that are one or two steps away from cirrhosis.

40:15Everyone knows the outcome there is very bad. So I think what the market is missing is how big our opportunity is and how good a profile we have. And being the first mover, it is a tremendous advantage. And we're not doing it as amateurs launching in this space. As I said, I've launched big products. My team's launched big products. We know what we're doing, and we know we can be successful, and we've shown that so far. You're also in phase three for ResDifra to treat the early stages of cirrhosis itself. So not just two steps before, one step before, but actually in early stages of cirrhosis.

40:46I want to go back to what you said about competing, because it sounds like you are definitively taking yourself off the table, off the board in terms of being an acquisition target. Well, I mean, look, we're a public company. What I do every day and my team does every day, we wake up to build the most value that we can. And that starts with treating as many patients that have this high unmet need. And we think that serves shareholders well by growing a valuable company. We're a public company, though. We can't control what people do. Bill, great to see you. Thank you. Bill Sibold, CEO of Madrigal.

41:15Thank you for having me. Coming up by Charles Schwab, end of the day in the red, despite reporting a surge in trading revenue. More Fast Money in two.

41:28Welcome back to Fast Money. Shares of Charles Schwab down today, despite top and bottom line beats in its Q3 report, shares had been up 3 % earlier in the day. Daily trading volume was up 30 % from a year ago. It added at least a million new brokerage accounts in the quarter. You flagged this one. You thought it was acting terribly. You know, I love looking in the beginning of earnings season and see how stocks react to good news. And this was obviously good news. This is a stock, though, that has not confirmed any of the new highs in the S &P 500 over the last month or so. So I guess we come into this.

41:56We know that trading has been robust. We heard it from the big banks. This is a different sort of trading, but we know that it's been a great period. So the fact that the stock closes on its load today, I'm just really not that optimistic that investors are willing to reward that news right now. Yeah, actually, I think there's a lot of positive news on what this could mean for the overall markets and the overall space, because I do think that trading activity is important. They're specifically in that retail trader. They, I think, a third of their new clients were Gen Z and another third of their new clients were millennials.

42:24They're actually really getting that younger generation who is actively trading a lot. And I do think that was very good for them, but I think that's going to be good for the broader space in general. All right. Up next, final trades.

42:43Final trade time. Stephen. I'm going with the best position. Quantum Company, Church Hill Capital Corp., soon to be inflection. Courtney. Schwab, we talked about this a minute ago, but it is down even after some positive earnings. I think you want to look at this. Dan, Nathan. Yeah, Oracle. I'm not assigning a multiple to sales out of four years. So I'd fade Oracle. Guy. Those CNBC Fast Money calendars are hot. Flying off the shelf, baby. They're not sold. They're not being sold. No, they're not. You have to come to Fast Money Live. You get one if you buy a ticket. Anyway, final straight, please.

43:17Bye, dude. Thank you for watching Fast Money. See you back here tomorrow at 5. Mad Money with Jim Cramer starts right now.

43:29All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

44:03To view the full Fast Money disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.

From the publisher

Stocks pulling back as the 10-year yield breaks below 4%. The sectors getting hit the hardest, and how the traders are handling the market volatility. Plus China’s rising chip demand. What a top tech analyst sees from the mainland, and the names he says will benefit from the overseas AI demand.

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Volatility Spikes As Rates Drop… And China’s Growing Chip Demand 10/16/25CNBC's "Fast Money" · 44 min
Listen in VO